You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 5,811,451

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,811,451

Title:	Pharmaceutical compositions comprising an opiate antagonist and calcium salts, their use for the treatment of endorphin-mediated pathologies
Abstract:	The combined use of opiate antagonists and of calcium salts for the preparation of medicaments for the treatment of endorphin-mediated pathologies is described.
Inventor(s):	Minoia; Paolo (I-70013 Castellana Grotte, (Bari), IT), Sciorsci; Raffaele Luigi (I-70014 Conversano, (Bari), IT)
Assignee:
Application Number:	08/737,902
Patent Claims:	1. The method of treatment of a living subject suffering from an endorphin-mediated pathology which consists of administering to said living subject a composition comprising an opiate antagonist (a) and a bioavailable calcium salt (b). 2. The method according to claim 1 wherein said opiate antagonist is a member selected from the group consisting of naloxone, naltrexone, dipremorphine, nalbuphine, betachloro-naltrexonine, naltrexonazine, naloxazone, nalmefene, beta-funaltrexamine, ICI 174.864, 7-benzylidenenaltrexone (BNTX), naltrindole, norbinaltorphimine, norbinaltorphammine, naltribene (NTB), profadol, quadazocine, naloxonazine, D-Pen-Cys-Tyr-D-Trp-Orn-Thr-Pen-NH2 (CTOP), MR-2266, naltrindole-5'-isothiocyanate(5'-NTII), N-methyl-D-aspartate (NMDA), dextrorphane, methylnaltrexone (MNTX), DALCE(D-Ala2, Leu5, Cys6-enkephalin), methylnaloxonium, bremazocine and LY 27614. 3. The method according to claim 1 wherein said composition additionally contains at least one member selected from the group consisting of proteases, prostaglandins, phorbol, Vitamin C and Vitamin K. 4. The method according to claim 3 wherein said composition contains a protease and the protease is a member selected from the group consisting of bromeline, papaine, chymotrypsine, trypsine, pepsine, subtilisine, proteinase A and K, kallicreine, elastase, chymopapaine, clostripaine, collagenase, metalloendopeptidase and ficines. 5. The method according to claim 1 wherein said administration is carried out intravenously, parenterally or orally. 6. The method according to claim 1 wherein said pathology is rachitism, said bioavailable calcium salt is calcium gluconate and said opiate antagonist is naloxone. 7. The method according to claim 1 wherein said pathology is an inflammatory condition, an infectious disease, osteoporosis and an autoimmune disease. 8. The method according to claim 1 wherein said calcium salt is a soluble calcium salt compatible with the pharmaceutical use and is a member selected from the group consisting of calcium ascorbate, gluconate, glucoheptonate, dobesilate, glucobionate, levulinate, lactate, lactobionate, pantotenate, ketoglutarate, and borogluconate. 9. The method according to claim 1 wherein said living subject is a cow affected by milk fever, said opiate antagonist is naloxone and said calcium salt is calcium borogluconate. 10. The method according to claim 1 wherein said living subject is a cow affected by milk fever meteorism and said opiate antagonist is naloxone and said calcium salt is calcium gluconate. 11. The method according to claim 1 wherein said living subject is a dog affected by parvovirus gastroenteritis, said opiate antagonist is naloxone and said calcium salt is calcium gluconate. 12. The method according to claim 1 wherein said living subject is a cow affected by parenchymatous mastitis, said opiate antagonist is naloxone hydrochloride, said calcium salt is calcium gluconate. 13. The method according to claim 1, said living subject is a dog affected by distemper, said opiate antagonist is naloxone hydrochloride and said calcium salt is calcium gluconate. 14. The method according to claim 3 wherein said living subject is a woman affected by luteinized unrupted follicle, said opiate antagonist is naloxone, and said composition contains Vitamin C. 15. The method according to claim 1 wherein the living subject is a cow suffering from damage of the corpus luteum, said opiate antagonist is naloxone and said calcium salt is calcium borogluconate. 16. The method according to claim 1 wherein said living subject is a horse affected by cholic syndrome, said calcium salt is calcium gluconate and said opiate antagonist is naloxone. 17. The method according to claim 1 wherein said living subject is a dog affected by hypertrophic osteodistrophy, said calcium salt is calcium borogluconate and said opiate antagonist is naloxone.

Details for Patent 5,811,451

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965	⤷ Try a Trial	2014-05-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.